07:06 EDT Akero Therapeutics (AKRO) sees cash, equivalents funding operating plan into 2028
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKRO:
- Promising Phase 2b Results for Akero Therapeutics’ Efruxifermin Highlight Potential for FDA Approval Despite Key Risk Score Challenges
- Promising Phase 2b Results and Future Prospects for Akero Therapeutics’ Efruxifermin Boost Buy Rating
- Akero Therapeutics announces new analyses of Phase 2b HARMONY trial
- Akero Therapeutics announces publication of Phase 2b SYMMETRY trial
- Akero Therapeutics reports results from Phase 2b SYMMETRY trial